Search
Close this search box.

Author name: Claritas Rx

competitive insights

Unlocking Competitive Data Insights in Therapy Basket Fill Rates

In the biopharma industry, understanding how your therapy basket’s fill rate stacks up against competitors can be a game-changer. This blog post dives deep into the significance of therapy basket fill rates, providing exclusive data insights and practical tips to help biopharma executives stay ahead in the competitive landscape. The Importance of Therapy Basket Fill […]

Unlocking Competitive Data Insights in Therapy Basket Fill Rates Read More »

calquence mcl

Breakthrough in Mantle Cell Lymphoma Treatment AstraZeneca’s Calquence Sets New Standard

Mantle cell lymphoma (MCL) is a rare yet aggressive form of non-Hodgkin lymphoma, and treatment options have been limited for far too long. For pharmaceutical professionals and biopharma executives, staying at the forefront of treatment innovations is crucial. Recently, AstraZeneca has made significant strides with its BTK inhibitor, Calquence, challenging the current standard of care

Breakthrough in Mantle Cell Lymphoma Treatment AstraZeneca’s Calquence Sets New Standard Read More »

fda guide

FDA Introduces Draft Guidance for Platform Technologies: A New Pathway to Fast-Track Cell and Gene Therapy Approvals

The FDA unveiled a much-anticipated draft guide, outlining how businesses can secure approvals for platform technologies. This regulatory advance has the potential to fast-track the FDA’s ‘platform technology’ procedure, potentially accelerating the endorsement of cell and gene therapies. Keen to find out more? This comprehensive 15-page draft guide provides a wealth of knowledge for biopharma

FDA Introduces Draft Guidance for Platform Technologies: A New Pathway to Fast-Track Cell and Gene Therapy Approvals Read More »

AstraZeneca growth

The Next Level of Growth: AstraZeneca Targets $80 Billion Revenue by 2030

AstraZeneca is experiencing tremendous success and progress under the leadership of CEO Pascal Soriot. His current objective is to achieve a revenue target of $80 billion by 2030. A decade ago, when AstraZeneca was experiencing a period of stagnation, the CEO projected a bold revenue goal of $45 billion by 2023. In a triumphant turn

The Next Level of Growth: AstraZeneca Targets $80 Billion Revenue by 2030 Read More »

FDA Approves Amgen’s Bkemv

Innovations in Biopharma: FDA Approves Amgen’s First Interchangeable Biosimilar

The U.S. Food and Drug Administration (FDA) has given the green light to Amgen’s monoclonal antibody Bkemv, the first interchangeable biosimilar for Alexion’s top-selling drug Soliris. This provides a pathway for more affordable treatments for rare blood diseases. Let’s take a closer look at what this means for the industry, medical practitioners, and patients. Deciphering

Innovations in Biopharma: FDA Approves Amgen’s First Interchangeable Biosimilar Read More »

Depemokimab

An Exciting Leap in Asthma Treatment: GSK’s New Experimental Drug Clears Two Phase 3 Trials

Tuesday brought good news for asthma sufferers and the healthcare community alike, courtesy of GSK. The pharmaceutical firm announced the successful reduction of annual asthma attacks in two pivotal clinical trials of its experimental antibody treatment named Depemokimab. The trials involved adults and adolescents afflicted with a form of severe asthma. GSK’s newly developed long-lasting

An Exciting Leap in Asthma Treatment: GSK’s New Experimental Drug Clears Two Phase 3 Trials Read More »

AI-powered drug R&D software

Big Pharma and Tech Combine Power: Unlocking AI’s Potential to Revolutionize Drug Development

In an exciting development for the biopharma industry, Sanofi, OpenAI, and Formation Bio have announced a unique partnership aiming to develop AI-powered drug R&D software. This strategic alliance is a testament to the increasingly intertwined future of the technology and pharmaceutical sectors. This announcement follows closely on the heels of OpenAI’s other significant alliance with

Big Pharma and Tech Combine Power: Unlocking AI’s Potential to Revolutionize Drug Development Read More »

gene and cell therapy

Pioneering a New Chapter in Healthcare: Walgreens Diversifies into Gene and Cell Therapies

Walgreens, a powerhouse in the retail and wholesale pharmaceutical sector, embarked on an unprecedented path with an impressive service upgrade – the incorporation of gene and cell therapies. This strategy extends Walgreens’ existing service portfolio and significantly advances healthcare. Let’s explore this groundbreaking endeavor and what it means for customers. Walgreens is expanding its specialty

Pioneering a New Chapter in Healthcare: Walgreens Diversifies into Gene and Cell Therapies Read More »

biosimilars

FDA-Approved Swap-In Biosimilars: Progressive Achievements or Pathway to Unexpected Barriers?

The Food and Drug Administration (FDA) has recently been the center of attention in the biopharmaceutical world, pushing for a notable shift in the discourse surrounding biosimilars. The federal agency has openly campaigned for the abolition of ‘interchangeability‘ – a term it perceives as causing more confusion than clarity and adversely impacting the market penetration

FDA-Approved Swap-In Biosimilars: Progressive Achievements or Pathway to Unexpected Barriers? Read More »